Last updated on November 2018

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma


Brief description of study

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.

Clinical Study Identifier: NCT02673333

Contact Investigators or Research Sites near you

Start Over

Diane Reidy-Lagunes, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.